Nephrocare Health Services IPO Listing at 7% Premium at ₹460 Per Share

Nephrocare Health Services IPO listing: The Nephrocare Health Services IPO was subscribed 14.08 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 26.82 times, and non-institutional investors (NIIs) received 24.77 times. The retail quota of the issue was subscribed to 34.85%. Before delving deeper into the topic, go through the details of the Nephrocare Health Services IPO.

Nephrocare Health Services IPO 

It is a book-building issue of ₹871.05 crore of shares. The issue is entirely a fresh issue of 0.77 crore shares. The IPO is expected to be listed on the BSE and NSE with a tentative listing date of 17th December 2025. The Vidya Wires IPO is expected to take place from 10th December 2025 to 12th December 2025. The face value of Vidya Wires IPO shares is ₹2 per share, and the IPO price is set at ₹460 per share.

Nephrocare Health Services IPO Listing

On the NSE platforms, Nephrocare Health Services shares are listed at ₹490 per share, reflecting a 7% premium over the issue price of ₹460 per share. On the other hand, on the BSE platform, shares are listed at ₹491.70 per share, reflecting a premium of 6.89% from their issue price of ₹460 per share.

About the Nephrocare Health Services IPO 

Nephrocare Health Services was established in 2010. Nephrocare Health Services Ltd. provides end-to-end dialysis care through a vast network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy. As of Sep 30, 2025, Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.53% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions. During Fiscal 2025, Nephrocare served 29,281 patients and completed 2,885,450 dialysis treatments, accounting for roughly 10% of the country’s total dialysis patient base. Additionally, by Sep 30, it has served 31,046 patients and completed 1,591,377 treatments in India. As of Sep 30, 2025, the company has 5,562 dialysis machines.

Nephrocare Health Services Limited Financials

The company’s financial analysis is essential before applying for Nephrocare Health Services Limited’s IPO. Refer to the table to learn about Vidya Wires Limited’s financial information. 

Explanation

Nephrocare Health Services Limited’s revenue increased by 34% from ₹574.72 crores in March 2024  to ₹769.92 crores in March 2025. Moreover, the company’s PAT increased by 91% from ₹35.13 crores in March 2024 to ₹67.10 crores in March 2025.

Recent Articles

Best Penny Stocks for Long Term in India | Penny Stocks in 2025

Berger Paints Q1 Results FY26: Q1 PAT Narrows 11.01% to ₹314.63 Crore; Revenue Surged 3.55% YoY

Tega Industries Q1 Results FY26: Q1 PAT Falls 3.83% to ₹35.34 Crore; Revenue Jumps 4.74% YoY

Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY

BLS International Services Q1 Results FY26: Q1 PAT Soars 49.76% to ₹171.00 Crore; Revenue Up 44.23% YoY